Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Fang Fund is an equity investment fund and focuses on new economic fields, with a particular focus on big data, new media, intelligent technology (AR/VR), alternative energy resources, new materials and health care. Fang Fund Partners management team has years of successful business practices and venture investment experience. The team is committed to providing value-added services for invested companies, grafting quality social resources and aligning with the ecological industry chain. Fang Fund Partners vision is to become a fund that understands entrepreneurs best and helps them fulfill their dreams, in an effort to promote social progress and contribute to the welfare of human beings. Fang Fund Partners have unique insight into startup experience of honorable entrepreneurs. Fang Fund Partners Advantages A wide range of project sources: ν Over 30,000 quality project sources each year ν Parallel investment in Greater China, United States (East and West Coast), Israel and Europe Abundant industrial resources ν Fund’s partners include well-known entrepreneurs and industrial leaders ν Fund’s management team has rich practical experience and industrial resources Solid value-adding services ν Fang Fund Partners can support the invested companies in various aspects, such as capital, big data, human resources, marketing &a; sales strategy and industry cooperation ν Fang Fund Partners can bring a broader international perspective and comprehensive strategic plans to our invested companies
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2014 | 123haitao.com | Angel Round | 488.3k |
1/2023 | Baikang Bio | Series A | 13.4M |
2/2022 | Easy Chat Technology | Series B | 15.8M |
5/2016 | ShareBang | Seed Round | 1.5M |
5/2016 | zooz | Series C | 0 |
4/2015 | Science For Life | Series A | 1.6M |
2/2018 | YunSpace | Series B | - |
12/2022 | Boaoxin | Series B | - |
12/2022 | 4B Technologies | Series B | 0 |
12/2020 | Denovo Biopharma | Series D | 0 |
1/2023 | Bioantibody | Series A | 14.8M |
1/2013 | Long Institute | Series A | 1.6M |
7/2018 | Qingmu Apartment | Venture Round | - |
10/2014 | 72 Bian | Angel Round | 489.7k |
1/2016 | Yunzhou Intelligence Technology | Series B | 23.1M |
1/2014 | Zannan | Series B | 3.3M |
12/2018 | Yimi Station | Series A | 2.9M |
1/2015 | Sunointech | Series A | 1.6M |
3/2014 | Sunointech | Angel Round | 488.8k |
12/2018 | TCR Cure | Series A | 1.5M |
1/2014 | Yunzhou Intelligence Technology | Series A | 3M |
2/2022 | Easy Chat Technology | Series B | 0 |
12/2020 | Denovo Biopharma | Series D | 0 |
12/2018 | Yimi Station | Series A | 0 |
12/2018 | TCR Cure | Series A | 0 |
7/2018 | Qingmu Apartment | Venture Round | - |
2/2018 | YunSpace | Series B | - |
5/2016 | zooz | Series C | 0 |
5/2016 | ShareBang | Seed Round | 0 |
1/2016 | Yunzhou Intelligence Technology | Series B | 0 |
4/2015 | Science For Life | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|